Nanopublications LDF server

Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }

• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
• SENTENCE label "Compared with the standard of care (SOC), Bayesian network meta-analysis (NMA) showed that dexamethasone led to lower risk of mortality with an odds ratio (OR) of 0.85 (95% CrI [0.76, 0.95]; moderate certainty) and lower risk of mechanical ventilation (MV) with an OR of 0.68 (95% CrI [0.56, 0.83]; low certainty)." provenance.
• SENTENCE label "Compared with the standard of care (SOC), Bayesian network meta-analysis (NMA) showed that dexamethasone led to lower risk of mortality with an odds ratio (OR) of 0.85 (95% CrI [0.76, 0.95]; moderate certainty) and lower risk of mechanical ventilation (MV) with an OR of 0.68 (95% CrI [0.56, 0.83]; low certainty)." provenance.
• SENTENCE label "Compared with the standard of care (SOC), Bayesian network meta-analysis (NMA) showed that dexamethasone led to lower risk of mortality with an odds ratio (OR) of 0.85 (95% CrI [0.76, 0.95]; moderate certainty) and lower risk of mechanical ventilation (MV) with an OR of 0.68 (95% CrI [0.56, 0.83]; low certainty)." provenance.
• SENTENCE label "Compared with the standard of care (SOC), Bayesian network meta-analysis (NMA) showed that dexamethasone led to lower risk of mortality with an odds ratio (OR) of 0.85 (95% CrI [0.76, 0.95]; moderate certainty) and lower risk of mechanical ventilation (MV) with an OR of 0.68 (95% CrI [0.56, 0.83]; low certainty)." provenance.
• SENTENCE label "The average mass loads of PGE2 and 5-iPF2&#945;-VI in a community were significantly increased (two-tailed p < 0.001) from the first month of COVID-19 pandemic to the second month; however, significantly decreased (two-tailed p < 0.001) in the third month." provenance.
• SENTENCE label "The average mass loads of PGE2 and 5-iPF2&#945;-VI in a community were significantly increased (two-tailed p < 0.001) from the first month of COVID-19 pandemic to the second month; however, significantly decreased (two-tailed p < 0.001) in the third month." provenance.
• SENTENCE label "The average mass loads of PGE2 and 5-iPF2&#945;-VI in a community were significantly increased (two-tailed p < 0.001) from the first month of COVID-19 pandemic to the second month; however, significantly decreased (two-tailed p < 0.001) in the third month." provenance.
• SENTENCE label "The average mass loads of PGE2 and 5-iPF2&#945;-VI in a community were significantly increased (two-tailed p < 0.001) from the first month of COVID-19 pandemic to the second month; however, significantly decreased (two-tailed p < 0.001) in the third month." provenance.
• SENTENCE label "The average mass loads of PGE2 and 5-iPF2&#945;-VI in a community were significantly increased (two-tailed p < 0.001) from the first month of COVID-19 pandemic to the second month; however, significantly decreased (two-tailed p < 0.001) in the third month." provenance.
• SENTENCE label "The average mass loads of PGE2 and 5-iPF2&#945;-VI in a community were significantly increased (two-tailed p < 0.001) from the first month of COVID-19 pandemic to the second month; however, significantly decreased (two-tailed p < 0.001) in the third month." provenance.
• SENTENCE label "The average mass loads of PGE2 and 5-iPF2&#945;-VI in a community were significantly increased (two-tailed p < 0.001) from the first month of COVID-19 pandemic to the second month; however, significantly decreased (two-tailed p < 0.001) in the third month." provenance.
• SENTENCE label "The average mass loads of PGE2 and 5-iPF2&#945;-VI in a community were significantly increased (two-tailed p < 0.001) from the first month of COVID-19 pandemic to the second month; however, significantly decreased (two-tailed p < 0.001) in the third month." provenance.
• SENTENCE label "The average mass loads of PGE2 and 5-iPF2&#945;-VI in a community were significantly increased (two-tailed p < 0.001) from the first month of COVID-19 pandemic to the second month; however, significantly decreased (two-tailed p < 0.001) in the third month." provenance.
• SENTENCE label "The average mass loads of PGE2 and 5-iPF2&#945;-VI in a community were significantly increased (two-tailed p < 0.001) from the first month of COVID-19 pandemic to the second month; however, significantly decreased (two-tailed p < 0.001) in the third month." provenance.
• SENTENCE label "The average mass loads of PGE2 and 5-iPF2&#945;-VI in a community were significantly increased (two-tailed p < 0.001) from the first month of COVID-19 pandemic to the second month; however, significantly decreased (two-tailed p < 0.001) in the third month." provenance.
• SENTENCE label "The average mass loads of PGE2 and 5-iPF2&#945;-VI in a community were significantly increased (two-tailed p < 0.001) from the first month of COVID-19 pandemic to the second month; however, significantly decreased (two-tailed p < 0.001) in the third month." provenance.
• SENTENCE label "The average mass loads of PGE2 and 5-iPF2&#945;-VI in a community were significantly increased (two-tailed p < 0.001) from the first month of COVID-19 pandemic to the second month; however, significantly decreased (two-tailed p < 0.001) in the third month." provenance.
• SENTENCE label "The average mass loads of PGE2 and 5-iPF2&#945;-VI in a community were significantly increased (two-tailed p < 0.001) from the first month of COVID-19 pandemic to the second month; however, significantly decreased (two-tailed p < 0.001) in the third month." provenance.
• SENTENCE label "The average mass loads of PGE2 and 5-iPF2&#945;-VI in a community were significantly increased (two-tailed p < 0.001) from the first month of COVID-19 pandemic to the second month; however, significantly decreased (two-tailed p < 0.001) in the third month." provenance.
• SENTENCE label "The average mass loads of PGE2 and 5-iPF2&#945;-VI in a community were significantly increased (two-tailed p < 0.001) from the first month of COVID-19 pandemic to the second month; however, significantly decreased (two-tailed p < 0.001) in the third month." provenance.
• SENTENCE label "So far, remdesivir and dexamethasone have shown clinical effectiveness in severe COVID-19 in hospitalized patients." provenance.
• SENTENCE label "So far, remdesivir and dexamethasone have shown clinical effectiveness in severe COVID-19 in hospitalized patients." provenance.
• SENTENCE label "So far, remdesivir and dexamethasone have shown clinical effectiveness in severe COVID-19 in hospitalized patients." provenance.
• SENTENCE label "So far, remdesivir and dexamethasone have shown clinical effectiveness in severe COVID-19 in hospitalized patients." provenance.
• SENTENCE label "So far, remdesivir and dexamethasone have shown clinical effectiveness in severe COVID-19 in hospitalized patients." provenance.
• SENTENCE label "So far, remdesivir and dexamethasone have shown clinical effectiveness in severe COVID-19 in hospitalized patients." provenance.
• SENTENCE label "So far, remdesivir and dexamethasone have shown clinical effectiveness in severe COVID-19 in hospitalized patients." provenance.
• SENTENCE label "So far, remdesivir and dexamethasone have shown clinical effectiveness in severe COVID-19 in hospitalized patients." provenance.
• SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
• SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
• SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
• SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
• SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
• SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
• SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
• SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
• SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
• SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
• SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
• SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
• SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
• SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
• SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
• SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
• SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
• SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
• SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
• SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
• SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
• SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
• SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
• SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
• SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
• SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
• SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
• SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
• SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
• SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
• SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
• SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
• SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
• SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
• SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
• SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
• SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
• SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
• SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
• SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
• SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
• SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
• SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
• SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
• SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
• SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.

• first
• previous
• next